Time Commitment: 3 Hrs 45 min over 56 days
Target Professions: DO, MD, Nurse Practitioner, Physician Assistant, Nurse
Target Specialties: Family Medicine, Hematology, Hematology/Oncology, Internal Medicine, Oncology, Urology, Women's Health
Credits Available: 3.75 AMA PRA Category 1 Credit

Renal cell carcinoma (RCC) remains the most common variety of renal cancer, representing 90% of the diagnoses. Within the United States (US), it is a relatively common malignant caner, ranking as sixth and tenth most common for men and women respectively. Yet, the incidence has been slowly but steadily rising over the past thirty years. While localized RCC has a high survival rate, metastatic RCC only has a 5-20% 5-year survival rate. Previous forms of therapy at this stage had variable efficacy and poor tolerability in these advanced stages. The development of several agents has improved RCC outcomes and have improved tolerability: vascular endothelial growth factor inhibitors (VEGFi), mammalian target of rapamycin inhibitors, and immunotherapies. Of note, two main combinations of are approved in patients with RCC: (1) tyrosine kinase inhibitors (TKIs) with immuno-oncology (I-O) therapies and (2) two I-O agents. Educational programs that focus on this new and emerging approach are needed to aid clinicians in understanding the proper and safe use of I-O combinations. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with renal cell carcinoma.

CME/CE Accreditation Information

Self Study

Live Group Discussions

  • Meet and Greet

    Please join me for a brief kick off where you'll have a chance to greet other group members and discuss our collective goals and priorities for the next few weeks. I’m really looking forward to seeing you.

  • Live Group Discussion #1: Key Insights on Renal Cell Carcinoma

    This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the self-study learning modules.

  • Live Group Discussion #2: Renal Cell Carcinoma Take-Home Messages: Putting the Evidence to Practice

    This virtual live discussion provides an opportunity for the group to convene with their group leader to discuss aspects of the case study responses and action plans.

Group Case Study

  • Renal Cell Carcinoma: Jacob's Case

    This group task activity has been designed for the learner to explore a patient case study and to apply the knowledge they have learned throughout the activity to determine the most appropriate way to treat the patient.

My Action Plan

  • Create an Action Plan

    In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with RCC.

Interested in becoming a Group Leader?

Renal Cell Carcinoma Expert Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

Telyssa Anderson, PharmD
Clinical Pharmacy Specialist
Archana Ajmera, NP
Jennifer Lloyd, APRN
Jasmine Patel, PharmD

Completed Groups

Biren Saraiya, MD
Assoc Prof of Medicine
Matthew Labriola, MD
Assistant Professor of Medicine
Abhishek Tripathi, MD
Associate Professor
Elaine Lam, MD
Associate Professor
Yousef Zakharia, MD
Associate Professor of Medicine
Bassel Nazha, MD, MPH
GU Medical Oncologist
Manpreet Chadha, MD
Associate Professor
Yasser Ged, MBBS
Assistant Professor
Michael Atkins, MD
Deputy Director
Jacqueline Brown, MD
Assistant Professor
Lindsay Diamond, NP
Clinical Program Manager
Samuel Kareff, MD, MPH
Hematology/Oncology Fellow